Ons 21 feb / År 42 / Nr 5 2023

Axxam: Bringing innovation to partnership

Axxam, founded in 2001 as a spinoff from Bayer, is a privately-owned innovative partner research organization (iPRO) providing discovery services to its life sciences clients.

Axxam, an Italian innovative partner research organization (iPRO), provides discovery services from assay development and high-throughput screening (HTS) to hit validation across the whole of the life sciences, from pharmaceuticals, biotech and animal health, through crop protection, to cosmetics, fragrances, food and beverages.
“Compared with a traditional contract research organisation, an iPRO does not offer catalogue services, but instead builds a solution based on the individual client’s needs,” said Axxam co-founder & CEO, Stefan Lohmer. “We have a broad spread of expertise and around a third of our work is outside pharma. Our backgrounds and expertise mean that we know what companies want.”

Axxam goes Nordic
Axxam’s headquarters are in Milan, Italy, with business development offices across Europe, and the US. The company’s latest expansion is its new business development office at COBIS, the Copenhagen Bio Science Park, which opened on 1 September 2018. The location brings Axxam closer to an actively growing life sciences centre and existing clients.
“Copenhagen is evolving as a biotechnology centre,” said Lohmer. “We want to be able to work face-to-face with our clients and partners, sharing expertise. Our new facility at COBIS will bring us closer to the important Nordic life science, pharma and biotech environment, and I believe that this region will fit extremely well with our iPRO approach.”

Keeping close to the cutting edge
Cutting edge science is critically important to Axxam. Every year, the company invests a significant part of its revenues into new technologies. Over 80% of its employees are scientists, and around a half of these have a PhD.
“Being an iPRO means maintaining a balance between the services we offer to our clients on one side and our need to keep up-to-date in the new frontiers of science,” said Lohmer. “Clients working with Axxam can rely on a strong scientific background, passion and a problem-solving attitude where each project is equally important.”
Axxam has introduced new technological platform services in the cell-based and biochemical assay development field, including HTS, high-content screening (HCS), electrophysiology and hit follow-up projects, and uses automation and robotics to support the different processes. The company has five grant-supported programs in hot research areas such as induced pluripotent stem cells (iPSCs), neurodegeneration, optogenetically controlled cellular processes and autophagy.
“Our focus is on early biology, where we are seeing an exponential increase in knowledge, forming the basis for drug discovery and we are on the forefront of innovation,” said Lohmer.

Working in partnership
Axxam mostly works with small and medium companies, startups, and academia with interesting early biology, and moves research from findings to important assets.
“Whether it’s assay development, HTS, compound profiling or hit-to-lead assays, we deliver best-in-class tailored services to our clients. We see ourselves not just as a service company taking orders but as a reliable partner that actively proposes solutions,” said Lohmer.